SUPN

SUPN

USD

Supernus Pharmaceuticals Inc. Common Stock

$57.000+1.570 (2.832%)

リアルタイム価格

Healthcare
Drug Manufacturers - Specialty & Generic
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$55.430

高値

$57.400

安値

$54.610

出来高

4.00M

企業ファンダメンタルズ

時価総額

3.2B

業種

Drug Manufacturers - Specialty & Generic

United States

取引統計

平均出来高

0.82M

取引所

NGM

通貨

USD

52週レンジ

安値 $29.16現在値 $57.000高値 $57.65

関連ニュース

Analyst Upgrades

B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

B of A Securities analyst Pavan Patel initiates coverage on Supernus Pharmaceuticals with a Buy rating and announces Price Target of $65.

もっと見る
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65
Analyst Upgrades

TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

TD Cowen analyst Stacy Ku maintains Supernus Pharmaceuticals with a Buy and raises the price target from $45 to $60.

もっと見る
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60
GlobeNewswire

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system

もっと見る
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Analyst Upgrades

Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65

Piper Sandler analyst David Amsellem upgrades Supernus Pharmaceuticals from Neutral to Overweight and raises the price target from $40 to $65.

もっと見る
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to $65

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。